A new cancer therapy has shown promise in cats, paving the way for human testing. Researchers at U.C. San Francisco and U.C. Davis treated 20 cats with head and neck squamous cell carcinoma, using a drug that aims to block the protein STAT3 and boost the protein PD-1, which “stimulates the immune system’s attack on tumors,” said The Times of London. The treatment controlled the disease in 35% of the cats, increasing the average survival rate by two months.